Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial ...

Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select yours ...